News
The revenue for the cell therapy Carvykti and the EGFR-targeted lung cancer duo Rybrevant-Lazcluze contributed to double digit gains in oncology drug sales.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback